Strange: Bullish FATE Analysts Actually See -25.48% Downside

Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Fate Therapeutics Inc (FATE). The average 12-month price target for FATE — averaging the work of 13 analysts — reveals an average price target of $69.77/share..
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.